KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Accounts Payables (2018 - 2025)

Takeda Pharmaceutical (TAK) has 3 years of Accounts Payables data on record, last reported at $3.1 billion in Q1 2025.

  • For Q1 2025, Accounts Payables fell 15.63% year-over-year to $3.1 billion; the TTM value through Mar 2025 reached $3.1 billion, down 15.63%, while the annual FY2025 figure was $3.1 billion, 17.77% down from the prior year.
  • Accounts Payables reached $3.1 billion in Q1 2025 per TAK's latest filing, down from $3.7 billion in the prior quarter.
  • Across five years, Accounts Payables topped out at $4.9 billion in Q1 2023 and bottomed at $3.1 billion in Q1 2025.
  • Average Accounts Payables over 3 years is $3.9 billion, with a median of $3.7 billion recorded in 2024.
  • Peak YoY movement for Accounts Payables: dropped 24.73% in 2024, then fell 15.63% in 2025.
  • A 3-year view of Accounts Payables shows it stood at $4.9 billion in 2023, then decreased by 24.73% to $3.7 billion in 2024, then decreased by 15.63% to $3.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $3.1 billion in Q1 2025, $3.7 billion in Q1 2024, and $4.9 billion in Q1 2023.